# Adjuvanted rzv vaccine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/adjuvanted-rzv-vaccine

> The next catalyst for adjuvanted rzv vaccine, sponsored by GSK plc (GSK), is its topline data readout, May to Aug 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | adjuvanted rzv vaccine |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Cardiovascular Disease](https://sec-api.dev/indications/cardiovascular-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May to Aug 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Cardiovascular Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07712380 (A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05-02 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07712380

### May 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Cardiovascular Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07712380 (A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05-02 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07712380

## Same indication

- [AZD0780](https://sec-api.dev/pdufa/azd0780) (AZN)
- [Olpasiran](https://sec-api.dev/pdufa/olpasiran) (AMGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/adjuvanted-rzv-vaccine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Adjuvanted rzv vaccine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/adjuvanted-rzv-vaccine

```bibtex
@misc{secapidev_pdufa_adjuvanted_rzv_vaccine_20261116,
  title        = {Adjuvanted rzv vaccine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/adjuvanted-rzv-vaccine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_adjuvanted_rzv_vaccine_20261116","title":"Adjuvanted rzv vaccine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/adjuvanted-rzv-vaccine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
